Search Results 691-700 of 17945 for Cornea

1. TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study - Mayo Clinic

   Corneal decompensation unresponsive to medical management. 3. Decrease in proptosis of ≥ 2 mm in the study eye between Screening and Baseline. 4. Prior ...

2. A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma - Mayo Clinic

   Current evidence of corneal or retinal disorder/keratopathy including, but not limited to, bullous/band keratopathy, corneal abrasion, inflammation/ulceration, ...

3. Rotation Schedule and Descriptions - Curriculum - Mayo Clinic College of Medicine & Science

   Ophthalmic infections, including corneal transplant. Transplant infectious diseases. Specialists at Mayo Clinic Transplant CenterOpens in new tab perform ...

4. A Study Of Belantamab Mafodotin Administered In Combination With Lenalidomide And Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, And Dexamethasone (DRd) In Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible For Autologous Stem Cell Transplantation (TI-NDMM) - Mayo Clinic

   Current corneal epithelial disease except for mild punctate keratopathy. 13. Intolerance or contraindications to antiviral prophylaxis. 14. Unable to ...

5. A Study Testing the Effectiveness and Safety of KPL-301 in Patients with Giant Cell Arteritis - Mayo Clinic

   Transplanted organs (except corneal transplant performed more than 3 months prior to randomization). · Concurrent enrollment in another interventional clinical ...

6. Mayo Clinic Department of Ophthalmology - Doctors

   Mayo Clinic has one of the largest and most experienced practices in the United States, with campuses in Arizona, Florida and Minnesota. Staff skilled in dozens ...

7. Horner syndrome - Symptoms & causes - Mayo Clinic

   Decreased eye pupil size is a key sign of Horner syndrome. Typically, signs and symptoms of Horner syndrome include decreased pupil size, a drooping eyelid and ...

8. A Phase I, Multi-Center, Open Label, Dose De-escalation and Expansion Study of Gemcitabine and Cisplatin with AG120 or Pemigatinib for Advanced Cholangiocarcinoma - Mayo Clinic

   For Arm B only: Current evidence of clinically significant corneal (including but not limited to bullous/band keratopathy, corneal abrasion, inflammation ...

9. Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin for First-Line Treatment of Patients With Advanced NSCLC Without Actionable Genomic Alterations - Mayo Clinic

   - Clinically significant corneal disease - Known active or uncontrolled hepatitis B or C virus infection - Known HIV infection that is not well controlled - ...

10. A Study to Evaluate the Safety and Effectiveness of TEPEZZA® in Treating Patients with Chronic (Inactive) Thyroid Eye Disease - Mayo Clinic

    Corneal decompensation unresponsive to medical management in the study eye. Decrease in proptosis of ≥ 2 mm in the study eye between Screening and Baseline ...